Hypertrophic cardiomyopathy represents one of the most common inherited cardiac disorders encountered in clinical practice. While clinicians frequently manage dynamic left ventricular outflow tract obstruction, a substantial proportion of patients experience symptomatic nonobstructive hypertrophic cardiomyopathy. These individuals endure debilitating exertional dyspnea, fatigue, and diminished functional capacity despite the absence of an outflow gradient. Historically, therapeutic options for this nonobstructive cohort remained severely restricted to nonspecific symptom management, such as beta-blockers or non-dihydropyridine calcium channel blockers. However, these traditional pharmacological agents fail to directly address the primary disease mechanism: sarcomeric hypercontractility and impaired myocardial relaxation. Emerging evidence from the landmark ACACIA-HCM clinical trial demonstrates that aficamten, a next-generation selective cardiac myosin inhibitor, significantly alters the therapeutic landscape. By directly mitigating hyperdynamic contraction and promoting ventricular compliance, aficamten offers a targeted mechanistic intervention. Consequently, the latest imaging findings from ACACIA-HCM shed critical light on how cardiac structure and function adapt during chronic myosin inhibition.

Pathophysiological Hallmarks of Nonobstructive Hypertrophic Cardiomyopathy

Nonobstructive hypertrophic cardiomyopathy is primarily driven by excess cross-bridge formation between actin and myosin filaments within cardiac sarcomeres. This fundamental molecular abnormality generates hyperdynamic systolic contraction alongside severe diastolic dysfunction. Consequently, the left ventricular myocardium exhibits marked concentric hypertrophy, myocardial disarray, and interstitial fibrosis. Because the outflow tract remains unobstructed, elevated left ventricular filling pressures serve as the principal hemodynamic disturbance driving chronic symptoms. Furthermore, high filling pressures transmit backward into the left atrium, causing progressive atrial enlargement and pulmonary venous congestion. As a result, patients experience debilitating exercise intolerance and elevated risk of atrial arrhythmias. Traditional negative inotropes often provide inadequate symptomatic relief because they do not modify sarcomere biophysics. Moreover, conventional therapies frequently cause dose-limiting bradycardia or systemic hypotension before achieving adequate ventricular decongestion. Therefore, clinicians urgently need disease-modifying agents capable of directly normalizing sarcomeric kinetics. Targeted cardiac myosin inhibitors suppress excessive actin-myosin interactions, thereby reducing intracellular energetic stress and facilitating active myocardial relaxation.

The ACACIA-HCM Study Architecture and Methodological Framework

The ACACIA-HCM study evaluated the efficacy and structural impact of aficamten through a rigorous, randomized, double-blind, placebo-controlled phase 3 trial across multiple international centers. The trial enrolled 517 adult participants with symptomatic nonobstructive hypertrophic cardiomyopathy who remained symptomatic despite standard medical therapy. Researchers randomized participants in a 1:1 ratio to receive either once-daily aficamten or matching placebo for up to 72 weeks. The starting dose of aficamten was 5 mg daily, with individualized uptitration to a maximum dose of 20 mg based on serial echocardiographic assessments of left ventricular ejection fraction. Specifically, investigators conducted prespecified exploratory analyses to assess serial changes in cardiac structure and diastolic performance at 36 weeks and at the end of treatment. Furthermore, the statistical models adjusted for baseline covariates, resting intracavity obstruction, and pre-existing atrial fibrillation to guarantee robust causal inference. The study population was diverse and representative, featuring a mean participant age of 55 years and including 54% women. Consequently, this methodological rigor established a definitive baseline for characterizing structural reverse remodeling.

Echocardiographic Remodeling and Diastolic Hemodynamics

Serial echocardiographic examinations revealed profound, favorable changes in left ventricular mechanics following aficamten administration. Compared with placebo, aficamten produced a modest, controlled reduction in left ventricular ejection fraction of approximately 4.6% at 36 weeks. Importantly, this controlled decline directly reflects the intended therapeutic attenuation of pathological hypercontractility. Furthermore, aficamten significantly enhanced indices of active diastolic relaxation. Treated patients demonstrated meaningful improvements in septal early diastolic mitral annular velocity compared to placebo controls. Concurrently, left ventricular filling pressures decreased, as evidenced by marked reductions in the ratio of early mitral inflow velocity to early diastolic mitral annular velocity. In addition, aficamten therapy promoted favorable structural remodeling of the left atrium. Specifically, investigators recorded a substantial decrease in left atrial volume index among patients receiving active treatment. Because left atrial volume directly reflects chronic left ventricular filling pressure, this structural reduction confirms sustained hemodynamic unloading. Moreover, linear regression models confirmed that these structural and functional improvements persisted through the extended 72-week treatment duration, underscoring durable structural reverse remodeling.

Biomarker Dynamics and Functional Exercise Capacity

Beyond structural imaging improvements, aficamten elicited pronounced reductions in circulating biomarkers of myocardial wall stress and cellular injury. Serum N-terminal pro-B-type natriuretic peptide levels declined by more than 50% in the aficamten cohort compared to minimal changes in the placebo group. Consequently, this dramatic biomarker suppression aligns with observed reductions in left ventricular filling pressures and left atrial wall tension. Additionally, cardiac troponin concentrations stabilized, indicating reduced ongoing cardiomyocyte injury. These physiological improvements translated directly into meaningful clinical benefits for patients. Aficamten significantly enhanced exercise capacity, as measured by objective peak oxygen uptake during cardiopulmonary exercise testing. Furthermore, a significantly higher proportion of aficamten-treated patients experienced improvement of at least one New York Heart Association functional class. Patient-reported health status also demonstrated significant gains, reflected by higher scores on the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score. Ultimately, multi-domain responder analyses confirmed that over half of aficamten recipients achieved comprehensive clinical and structural responses.

Safety Monitoring, Dose Titration, and Clinical Perspectives

Clinical implementation of cardiac myosin inhibitors requires vigilant echocardiographic surveillance to balance therapeutic efficacy with safety. In the ACACIA-HCM trial, investigators noted left ventricular ejection fraction reductions below 50% in approximately 10.5% of aficamten-treated patients, compared to under 1% with placebo. However, all episodes were transient and resolved promptly with planned protocolized dose down-titration or temporary interruption. Furthermore, aficamten exhibits a relatively short half-life, which enables rapid dose adjustments and steady-state reversibility. Serious adverse events occurred slightly more often in the active treatment group, emphasizing the necessity of standardized monitoring protocols. Nevertheless, the substantial clinical and structural gains offer immense therapeutic promise for an historically underserved patient demographic. In clinical practice, integrating aficamten will provide cardiologists with a first-in-class targeted medical therapy for nonobstructive pathology. In addition, routine echocardiography will guide safe titration schedules in tertiary care centers and specialized cardiomyopathy clinics. Consequently, these findings represent a transformative milestone in precision cardiovascular medicine.

What is the primary mechanism of action of aficamten in nonobstructive hypertrophic cardiomyopathy?

Aficamten is a next-generation, selective small-molecule cardiac myosin inhibitor. It directly binds to cardiac myosin, reducing the number of active actin-myosin cross-bridges during each contractile cycle. Consequently, it decreases pathological myocardial hypercontractility, relieves energetic stress within cardiomyocytes, and significantly improves diastolic active relaxation. This targeted mechanism reduces elevated left ventricular filling pressures and reverses adverse cardiac remodeling without impairing normal cardiac physiology.

How does aficamten impact left ventricular ejection fraction and safety parameters?

Aficamten intentionally induces a modest, dose-dependent decrease in left ventricular ejection fraction by reducing pathological hyperdynamic contraction. In the ACACIA-HCM trial, mean ejection fraction decreased by approximately 4.6%. Although around 10% of patients experienced transient reductions below 50%, these changes were fully reversible with dose adjustments. Aficamten’s short half-life supports rapid titration and safety recovery, requiring regular echocardiographic monitoring to optimize patient outcomes safely.

How does nonobstructive hypertrophic cardiomyopathy differ from the obstructive phenotype?

Obstructive hypertrophic cardiomyopathy features dynamic mechanical impedance to left ventricular outflow, creating substantial pressure gradients across the outflow tract. In contrast, nonobstructive hypertrophic cardiomyopathy lacks significant resting or provocable outflow tract gradients. However, patients with nonobstructive disease still suffer from marked myocardial hypertrophy, severe diastolic dysfunction, elevated intracardiac filling pressures, and debilitating exertional dyspnea, historically lacking targeted pharmacotherapy until the development of cardiac myosin inhibitors.

Disclaimer: This content is for informational and educational purposes only. It is not intended to substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified healthcare provider with any questions you may have regarding a medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Hegde SM et al. Effect of Aficamten on Cardiac Structure and Function in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. Circulation. 2026 Aug 29. doi: 10.1161/CIRCULATIONAHA.126.082343. PMID: 42667274.
2. Masri A, Owens A, Maron MS, et al. Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Primary Results of the ACACIA-HCM Trial. New England Journal of Medicine. 2026;395(9):812-824.
3. Maron BJ, Desai MY, Nishimura RA, et al. Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;79(4):372-389.